Immatics N.V. (IMTX) 股票分析

公司概述

Immatics N.V. operates as a clinical-stage biopharmaceutical entity dedicated to the research and development of potential T cell redirecting immunotherapies specifically designed for the treatment of cancer within the United States. The company functions within the Healthcare sector and the Biotechnology industry, a domain characterized by high-risk, high-reward innovation where capital is heavily allocated to advancing drug candidates through clinical trials. In terms of scale, the company holds a market capitalization of $1.43 billion, reported annual revenue of $48.27 million, and employs a workforce of 589 individuals. These valuation and revenue figures indicate that the market assigns a significant premium to the company's pipeline assets, despite the fact that the firm is currently in a clinical-stage development phase where commercial revenue generation is limited and operational costs remain substantial.

财务健康

The financial statements reveal a revenue of $48.27 million for the trailing twelve months, accompanied by a net income of $-196,447,008 and an EBITDA of $-172,875,008. The substantial gap between the positive revenue and the deeply negative net income and EBITDA highlights an aggressive cost structure typical of biotechnology firms, where research, development, and clinical trial expenses significantly outpace current sales. The company generated free cash flow of $-128,190,248, indicating that its current operations consume cash reserves rather than generating liquidity, which constrains immediate financial flexibility and necessitates external financing or burn of existing cash. Margin analysis shows a gross margin of -280.9%, an operating margin of -196.8%, and a profit margin of 0.0%, reflecting that operating expenses and cost of goods sold far exceed the revenue base on a percentage basis. Regarding balance sheet strength, the company holds $469.34 million in cash against $15.63 million in debt, resulting in a debt-to-equity ratio of 3.23, which suggests a leveraged position relative to equity but maintains a robust cash buffer against total liabilities. The current ratio stands at 11.72, indicating that the company possesses ample current assets to cover its short-term obligations, suggesting strong short-term liquidity despite the cash burn rate. Return on Equity is recorded at -37.1% and Return on Assets at -18.1%, metrics that reveal that management is currently unable to generate positive returns on the capital invested or assets held, consistent with the losses incurred during the clinical development stage.

估值评估

The valuation metrics present a trailing P/E ratio of N/A and a forward P/E of -6.04, implying that earnings are currently negative and the market is pricing the stock based on non-earnings fundamentals or future projected profitability that has not yet materialized. The price-to-book ratio is 2.55, suggesting that the market values the company at a premium of 155% over its tangible book value, likely reflecting the perceived potential of its intellectual property and clinical pipeline assets. Alternative valuation measures include a price-to-sales ratio of 29.62 and an EV/EBITDA of -5.64, which indicate that investors are paying a high multiple per dollar of revenue, a common characteristic of biotech firms with promising but unproven products. The stock has traded between a 52-week high of $12.41 and a 52-week low of $3.45, and without the current price explicitly provided in the data, the position relative to this range is defined by this historical volatility band. The beta value is 1.34, indicating that the stock exhibits 34% higher volatility than the broader market, meaning price swings will likely be more pronounced during periods of general market fluctuation.

Growth & Income

Revenue growth year-over-year is recorded at -64.9%, while earnings growth is listed as N/A, indicating that the company is currently shrinking in terms of top-line revenue and has not yet achieved positive earnings to measure growth rates against. The negative revenue growth rate implies a contraction in sales, which may be attributed to the cessation of previous sales cycles or the transition period associated with advancing clinical candidates that have not yet reached the market. As a non-dividend payer, the company has a dividend yield of N/A and a payout ratio of 0.0%, confirming that all available cash is being retained and reinvested into research and development activities rather than distributed to shareholders. Consequently, the overall growth and income profile is characterized by significant revenue contraction and a complete absence of dividend income, relying entirely on capital appreciation driven by clinical trial milestones rather than operational profitability or income generation.